Molecular typing of epithelial ovarian carcinomas using inflammatory markers

Cancer. 2011 Jan 15;117(2):301-9. doi: 10.1002/cncr.25588. Epub 2010 Sep 3.

Abstract

Background: Ovarian epithelial carcinomas have recently been classified as slow growing type I tumors and rapidly growing highly aggressive type II tumors. The present study sought to molecularly characterize type I and II tumors using known molecular markers.

Methods: Specimens from 213 patients with ovarian carcinoma were categorized as type I or type II, and evaluated by immunohistochemistry for the inflammatory markers glucose transporter protein-1 (Glut-1), inducible nitric oxide synthase (iNOS), cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and nuclear factor kappa B. Statistical analysis was performed to investigate whether these molecular markers could distinguish between type I and type II tumors. Kaplan-Meier survival curves and COX regression analysis were used to determine the prognostic effect of these markers on survival in the 2 types of tumors.

Results: Overexpression of COX-1, COX-2, iNOS, and Glut-1 was significantly higher in type II tumors (P < .05). Women with type II tumors had a poorer median survival (60 months) as compared with those with type I tumors (141 months) (P = .0001). Multivariate analysis revealed type II tumors, late stage, and age >60 years as significant predictors of poor survival. For type II tumors, median survival of patients with tumors overexpressing COX-2 was 44 compared with 85 months for those with tumors with low COX-2 expression (P = .029). Looking at both type I and II tumors, the number of markers simultaneously overexpressed in each tumor was a significant predictor of poor patient survival (P = .005).

Conclusions: The present study demonstrates that the new proposed histologic classification of ovarian epithelial carcinomas correlates with a distinct expression of inflammatory pathway proteins. High expression of these markers may explain the different biologic behavior of these 2 tumor types and provide targets for therapy.

Publication types

  • Evaluation Study

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Carcinoma, Ovarian Epithelial
  • Cyclooxygenase 1 / analysis
  • Cyclooxygenase 2 / analysis
  • Female
  • Glucose Transporter Type 1 / analysis
  • Humans
  • Immunohistochemistry
  • Inflammation / metabolism*
  • Middle Aged
  • NF-kappa B / analysis
  • Neoplasms, Glandular and Epithelial / diagnosis
  • Neoplasms, Glandular and Epithelial / mortality
  • Nitric Oxide Synthase Type II / analysis
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / mortality

Substances

  • Biomarkers, Tumor
  • Glucose Transporter Type 1
  • NF-kappa B
  • SLC2A1 protein, human
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 1
  • Cyclooxygenase 2